{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011071","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.915685+00:00","generated_at":"2026-05-31T12:18:39.293233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025","bullets":["Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.","Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.","First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.","Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.","Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011071","json":"https://secwatch.observer/filing/0001558370-24-011071.json","markdown":"https://secwatch.observer/filing/0001558370-24-011071.md","text":"https://secwatch.observer/filing/0001558370-24-011071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/0001558370-24-011071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/vygr-20240806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:39.293233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}